RSS-Feed abonnieren
DOI: 10.1055/s-2007-991969
The Role of Thrombomodulin in Malignancy
Publikationsverlauf
Publikationsdatum:
14. November 2007 (online)
![](https://www.thieme-connect.de/media/sth/200707/lookinside/thumbnails/10.1055-s-2007-991969-1.jpg)
ABSTRACT
More than 150 years ago, Trousseau first suggested a link between cancer and thrombosis. Although this link has been widely described subsequently, the underlying mechanism still remains unclear. Thrombomodulin (TM), a natural endothelial anticoagulant, has proved itself to be an exciting molecule of many functions, not least of those in inflammation, thrombosis, and carcinogenesis. It has been highlighted and supported in many studies as having a cytoprotective role in many types of carcinoma; however, the mechanism of this role remains undefined. It is clear that TM exerts an influence on the endothelium and on the metastatic capacity of cancer, with elevated TM expression conferring a positive predictive and prognostic factor. Exactly how TM features in the metastatic pathway is unclear; however, once this has been clearly outlined, the opportunities afforded by inducers of TM expression may provide potential therapies to improve tumor behavior and impede transendothelial spread of cancer.
KEYWORDS
Thrombomodulin - inflammation - thrombosis - malignancy
REFERENCES
- 1 Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. Lancet. 2001; 357 539-545
- 2 Esmon C T, Fukudome K, Mather T et al.. Inflammation, sepsis, and coagulation. Haematologica. 1999; 84 254-259
- 3 Esmon C T, Gu J M, Xu J, Qu D, Stearns-Kurosawa D J, Kurosawa S. Regulation and functions of the protein C anticoagulant pathway. Haematologica. 1999; 84 363-368
- 4 Conway E M, Van de Wouwer M, Pollefeyt S et al.. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med. 2002; 196 565-577
- 5 Donati M B, Falanga A. Pathogenetic mechanisms of thrombosis in malignancy. Acta Haematol. 2001; 106 18-24
- 6 Falanga A, Donati M B. Pathogenesis of thrombosis in patients with malignancy. Int J Hematol. 2001; 73 137-144
- 7 Rickles F R, Edwards R L. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood. 1983; 62 14-31
- 8 Donati M B. Cancer and thrombosis: from phlegmasia alba dolens to transgenic mice. Thromb Haemost. 1995; 74 278-281
- 9 Donati M B, Poggi A. Malignancy and hemostasis. Br J Haematol. 1980; 44 173-182
- 10 Esmon C T. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem. 1989; 264 4743-4746
- 11 Imada S, Yamaguchi H, Nagumo M, Katayanagi S, Iwasaki H, Imada M. Identification of fetomodulin, a surface marker protein of fetal development, as thrombomodulin by gene cloning and functional assays. Dev Biol. 1990; 140 113-122
- 12 Hosaka Y, Higuchi T, Tsumagari M, Ishii H. Inhibition of invasion and experimental metastasis of murine melanoma cells by human soluble thrombomodulin. Cancer Lett. 2000; 161 231-240
- 13 de Munk G A, Groeneveld E, Rijken D C. Acceleration of the thrombin inactivation of single chain urokinase-type plasminogen activator (pro-urokinase) by thrombomodulin. J Clin Invest. 1991; 88 1680-1684
- 14 Kokame K, Zheng X, Sadler J E. Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C. J Biol Chem. 1998; 273 12135-12139
- 15 Imada M, Imada S, Iwasaki H, Kume A, Yamaguchi H, Moore E E. Fetomodulin: marker surface protein of fetal development which is modulatable by cyclic AMP. Dev Biol. 1987; 122 483-491
- 16 Dorffler-Melly J, de Kruif M, Schwarte L A et al.. Functional thrombomodulin deficiency causes enhanced thrombus growth in a murine model of carotid artery thrombosis. Basic Res Cardiol. 2003; 98 347-352
- 17 Galli M. Non beta 2-glycoprotein I cofactors for antiphospholipid antibodies. Lupus. 1996; 5 388-392
- 18 Altomonte L, Zoli A, Accili D, Mangia A, Bianco A, Magaro M. Thrombosis, recurrent abortions and intrauterine foetal death in a patient with lupus anticoagulant. Clin Rheumatol. 1985; 4 455-457
- 19 Kaare M, Ulander V M, Painter J N, Ahvenainen T, Kaaja R, Aittomaki K. Variations in the thrombomodulin and endothelial protein C receptor genes in couples with recurrent miscarriage. Hum Reprod. 2007; 22 864-868
- 20 Nan B, Lin P, Lumsden A B, Yao Q, Chen C. Effects of TNF-alpha and curcumin on the expression of thrombomodulin and endothelial protein C receptor in human endothelial cells. Thromb Res. 2005; 115 417-426
- 21 Speiser W, Kapiotis S, Kopp C W et al.. Effect of intradermal tumor necrosis factor-alpha-induced inflammation on coagulation factors in dermal vessel endothelium. An in vivo study of human skin biopsies. Thromb Haemost. 2001; 85 362-367
- 22 Falanga A, Ofosu F A, Cortelazzo S et al.. Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. Br J Haematol. 1993; 85 745-750
- 23 Falanga A, Barbui T, Rickles F R, Levine M N. Guidelines for clotting studies in cancer patients. For the Scientific and Standardization Committee of the Subcommittee on Hemostasis and Malignancy International Society of Thrombosis and Hemostasis. Thromb Haemost. 1993; 70 540-542
- 24 Falanga A, Ofosu F A, Delaini F et al.. The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibitions. Blood Coagul Fibrinolysis. 1994; 5(Suppl 1) S19-S23 discussion 59-64
- 25 O'Meara R A. The growth-pattern of carcinomas. Arch De Vecchi Anat Patol. 1960; 31 365-384
- 26 O'Meara R A. Coagulative properties of cancers. Ir J Med Sci. 1958; 394 474-479
- 27 O'Meara R A, Thornes R D. Some properties of the cancer coagulative factor. Ir J Med Sci. 1961; 423 106-112
- 28 Thornes R D, Martin W T. The cytopathic effect of fibrinolytic agents and human placental fractions on HeLa cells. Ir J Med Sci. 1961; 431 487-494
- 29 Thornes R D, O'Meara R A. A method of detecting and estimating inhibitors of the cancer coagulative factor. Ir J Med Sci. 1961; 428 361-365
- 30 Thornes R D, Daly L, Lynch G et al.. Treatment with coumarin to prevent or delay recurrence of malignant melanoma. J Cancer Res Clin Oncol. 1994; 120(Suppl) S32-S34
- 31 Bereczky B, Gilly R, Raso E, Vago A, Timar J, Tovari J. Selective antimetastatic effect of heparins in preclinical human melanoma models is based on inhibition of migration and microvascular arrest. Clin Exp Metastasis. 2005; 22 69-76
- 32 Kawase M, Sakagami H, Motohashi N et al.. Coumarin derivatives with tumor-specific cytotoxicity and multidrug resistance reversal activity. In Vivo. 2005; 19 705-711
- 33 Elinos-Baez C M, Leon F, Santos E. Effects of coumarin and 7OH-coumarin on bcl-2 and Bax expression in two human lung cancer cell lines in vitro. Cell Biol Int. 2005; 29 703-708
- 34 Okamoto T, Kobayashi T, Yoshida S. Chemical aspects of coumarin compounds for the prevention of hepatocellular carcinomas. Curr Med Chem Anti-Canc Agents. 2005; 5 47-51
- 35 Yim D, Singh R P, Agarwal C, Lee S, Chi H, Agarwal R. A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells. Cancer Res. 2005; 65 1035-1044
- 36 Boccaccio C, Sabatino G, Medico E et al.. The MET oncogene drives a genetic programme linking cancer to hemostasis. Nature. 2005; 434 396-400
- 37 Stenina O I, Plow E F. MET orchestrates cancer and blood coagulation. Nat Med. 2005; 11 376-377
- 38 Blom J W, Doggen C J, Osanto S, Rosendaal F R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005; 293 715-722
- 39 Rickles F R, Levine M, Edwards R L. Hemostatic alterations in cancer patients. Cancer Metastasis Rev. 1992; 11 237-248
- 40 Yonezawa S, Maruyama I, Sakae K, Igata A, Majerus P W, Sato E. Thrombomodulin as a marker for vascular tumors. Comparative study with factor VIII and Ulex europaeus I lectin. Am J Clin Pathol. 1987; 88 405-411
- 41 Appleton M A, Attanoos R L, Jasani B. Thrombomodulin as a marker of vascular and lymphatic tumours. Histopathology. 1996; 29 153-157
- 42 Kim S J, Shiba E, Ishii H et al.. Thrombomodulin is a new biological and prognostic marker for breast cancer: an immunohistochemical study. Anticancer Res. 1997; 17 2319-2323
- 43 Jackson D E, Mitchell C A, Bird P, Salem H H, Hayman J A. Immunohistochemical localization of thrombomodulin in normal human skin and skin tumours. J Pathol. 1995; 175 421-432
- 44 Takebayashi Y, Yamada K, Maruyama I, Fujii R, Akiyama S, Aikou T. The expression of thymidine phosphorylase and thrombomodulin in human colorectal carcinomas. Cancer Lett. 1995; 92 1-7
- 45 Yonezawa S, Maruyama I, Tanaka S, Nakamura T, Sato E. Immunohistochemical localization of thrombomodulin in chorionic diseases of the uterus and choriocarcinoma of the stomach. A comparative study with the distribution of human chorionic gonadotropin. Cancer. 1988; 62 569-576
- 46 Tabata M, Yonezawa S, Sugihara K, Yamashita S, Maruyama I. The use of thrombomodulin to study epithelial cell differentiation in neoplastic and non-neoplastic oral lesions. J Oral Pathol Med. 1995; 24 443-449
- 47 Ogawa H, Yonezawa S, Maruyama I et al.. Expression of thrombomodulin in squamous cell carcinoma of the lung: its relationship to lymph node metastasis and prognosis of the patients. Cancer Lett. 2000; 149 95-103
- 48 Tabata M, Sugihara K, Yonezawa S, Yamashita S, Maruyama I. An immunohistochemical study of thrombomodulin in oral squamous cell carcinoma and its association with invasive and metastatic potential. J Oral Pathol Med. 1997; 26 258-264
- 49 Matsushita Y, Yoshiie K, Imamura Y et al.. A subcloned human esophageal squamous cell carcinoma cell line with low thrombomodulin expression showed increased invasiveness compared with a high thrombomodulin-expressing clone-thrombomodulin as a possible candidate for an adhesion molecule of squamous cell carcinoma. Cancer Lett. 1998; 127 195-201
- 50 Hanly A M, Redmond M, Winter D C et al.. Thrombomodulin expression in colorectal carcinoma is protective and correlates with survival. Br J Cancer. 2006; 94 1320-1325
- 51 Lindahl A K, Boffa M C, Abildgaard U. Increased plasma thrombomodulin in cancer patients. Thromb Haemost. 1993; 69 112-114
- 52 Boffa M C, Lapeyrere C, Berard M et al.. Plasma thrombomodulin level in malignancy varies according to the tumor type. Nouv Rev Fr Hematol. 1994; 36(Suppl 1) S87-S88
- 53 Raife T J, Lager D J, Madison K C et al.. Thrombomodulin expression by human keratinocytes. Induction of cofactor activity during epidermal differentiation. J Clin Invest. 1994; 93 1846-1851
- 54 Suehiro T, Shimada M, Matsumata T, Taketomi A, Yamamoto K, Sugimachi K. Thrombomodulin inhibits intrahepatic spread in human hepatocellular carcinoma. Hepatology. 1995; 21 1285-1290
- 55 Tezuka Y, Yonezawa S, Maruyama I et al.. Expression of thrombomodulin in esophageal squamous cell carcinoma and its relationship to lymph node metastasis. Cancer Res. 1995; 55 4196-4200
- 56 Huang H C, Shi G Y, Jiang S J et al.. Thrombomodulin-mediated cell adhesion: involvement of its lectin-like domain. J Biol Chem. 2003; 278 46750-46759
- 57 Markuljak I, Ivankova J, Kubisz P. Thrombomodulin and von Willebrand factor in smokers and during smoking. Nouv Rev Fr Hematol. 1995; 37 137-139
- 58 Conacci-Sorrell M, Zhurinsky J, Ben-Ze'ev A. The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest. 2002; 109 987-991
- 59 Imada S, Yamaguchi H, Imada M. Differential expression of fetomodulin and tissue plasminogen activator to characterize parietal endoderm differentiation of F9 embryonal carcinoma cells. Dev Biol. 1990; 141 426-430
- 60 Zhang Y, Weiler-Guettler H, Chen J et al.. Thrombomodulin modulates growth of tumor cells independent of its anticoagulant activity. J Clin Invest. 1998; 101 1301-1309
- 61 Yamaguchi Y, Hisama N, Okajima K et al.. Pretreatment with activated protein C or active human urinary thrombomodulin attenuates the production of cytokine-induced neutrophil chemoattractant following ischemia/reperfusion in rat liver. Hepatology. 1997; 25 1136-1140
- 62 Uchiba M, Okajima K, Murakami K, Johno M, Okabe H, Takatsuki K. Recombinant thrombomodulin prevents endotoxin-induced lung injury in rats by inhibiting leukocyte activation. Am J Physiol. 1996; 271(3 Pt 1) L470-L475
- 63 Calnek D S, Grinnell B W. Thrombomodulin-dependent anticoagulant activity is regulated by vascular endothelial growth factor. Exp Cell Res. 1998; 238 294-298
- 64 Seigneur M, Dufourcq P, Belloc F, Lenoble M, Renard M, Boisseau M R. Influence of pentoxifylline on membrane thrombomodulin levels in endothelial cells submitted to hypoxic conditions. J Cardiovasc Pharmacol. 1995; 25(Suppl 2) S85-S87
- 65 Ohdama S, Takano S, Ohashi K, Miyake S, Aoki N. Pentoxifylline prevents tumor necrosis factor-induced suppression of endothelial cell surface thrombomodulin. Thromb Res. 1991; 62 745-755
- 66 Shi J, Wang J, Zheng H et al.. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis. 2003; 14 575-585
- 67 Reny J L, Remones V, Fontana P et al.. The thrombomodulin-1208/-1209delTT gene promoter polymorphism does not affect basal or LPS-dependent monocyte TM mRNA transcription in healthy volunteers. Thromb Haemost. 2005; 94 686-687
- 68 Archipoff G, Beretz A, Freyssinet J M, Klein-Soyer C, Brisson C, Cazenave J P. Heterogeneous regulation of constitutive thrombomodulin or inducible tissue-factor activities on the surface of human saphenous-vein endothelial cells in culture following stimulation by interleukin-1, tumour necrosis factor, thrombin or phorbol ester. Biochem J. 1991; 273 679-684
Ann M HanlyM.D.
c/o Desmond C. Winter, M.D., Consultant General and Colorectal Surgeon
St. Vincents University Hospital, Dublin 4, Ireland
eMail: amhanly@indigo.ie